JPMorgan Chase & Co. Has $206.34 Million Holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Key Points

• JPMorgan Chase & Co. has increased its stake in Jazz Pharmaceuticals by 4.7%, bringing its total holdings to 1,662,042 shares valued at approximately $206 million as of the end of the first quarter.
• A number of hedge funds have also boosted their positions in Jazz Pharmaceuticals, with notable increases from Dimensional Fund Advisors by 18.7% and Ameriprise Financial by 20.9% in the previous quarter.
• Jazz Pharmaceuticals reported a loss of $8.25 per share for the last quarter, missing analysts' estimates, while revenue remained steady at $1.05 billion.

JPMorgan Chase & Co. lifted its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 4.7% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,662,042 shares of the specialty pharmaceutical company's stock after buying an additional 74,501 shares during the quarter. JPMorgan Chase & Co. owned approximately 2.70% of Jazz Pharmaceuticals worth $206,343,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the stock. Focus Partners Wealth acquired a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at approximately $551,000. CX Institutional acquired a new stake in shares of Jazz Pharmaceuticals in the first quarter valued at $4,316,000. Envestnet Portfolio Solutions Inc. raised its stake in shares of Jazz Pharmaceuticals by 38.9% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 4,369 shares of the specialty pharmaceutical company's stock valued at $542,000 after acquiring an additional 1,223 shares in the last quarter. GAMMA Investing LLC raised its stake in Jazz Pharmaceuticals by 63.7% in the first quarter. GAMMA Investing LLC now owns 1,015 shares of the specialty pharmaceutical company's stock valued at $126,000 after buying an additional 395 shares in the last quarter. Finally, Janney Montgomery Scott LLC acquired a new stake in Jazz Pharmaceuticals in the first quarter valued at $1,888,000. Hedge funds and other institutional investors own 89.14% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on JAZZ. Needham & Company LLC restated a "buy" rating and issued a $202.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, June 11th. Morgan Stanley cut their target price on Jazz Pharmaceuticals from $165.00 to $162.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 6th. Wall Street Zen cut Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 15th. Deutsche Bank Aktiengesellschaft began coverage on Jazz Pharmaceuticals in a report on Tuesday, July 15th. They set a "buy" rating and a $152.00 price target on the stock. Finally, Royal Bank Of Canada lowered their price objective on Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. Based on data from MarketBeat, Jazz Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $181.43.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ traded up $1.10 during midday trading on Friday, reaching $117.77. The stock had a trading volume of 490,600 shares, compared to its average volume of 808,948. Jazz Pharmaceuticals PLC has a 1-year low of $95.49 and a 1-year high of $148.06. The firm's fifty day simple moving average is $111.83 and its 200-day simple moving average is $117.22. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37. The stock has a market capitalization of $7.14 billion, a P/E ratio of -17.50, a PEG ratio of 7.97 and a beta of 0.34.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The company had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.05 billion. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%. The business's revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $5.30 earnings per share. On average, equities research analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the business's stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $107.63, for a total value of $107,630.00. Following the completion of the transaction, the chief executive officer directly owned 436,973 shares of the company's stock, valued at approximately $47,031,403.99. The trade was a 0.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 4.30% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.